A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (CEDAR)
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)
Sponsor: Allergan
This PHASE3 trial investigates Macular Degeneration and is currently completed. Allergan leads this study, which shows 18 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
18 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 13 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — Aug 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .